SCHEMBL5878323

SCHEMBL5878323

Cc1ccc(S(=O)(=O)n2nc(NC3CCC3)c3c2CC(c2ccccc2)(c2cncs2)C=C3)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 3/20 0.33
MAPT P10636 2/20 0.33
USP2 O75604 2/20 0.33
MAPK1 P28482 1/20 0.33
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
NOD2 Q9HC29 1/20 0.32
NOD1 Q9Y239 1/20 0.32
GBA1 P04062 1/20 0.32
NPSR1 Q6W5P4 2/20 0.31
LMNA P02545 2/20 0.31
TP53 P04637 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CCR6 P51684 1/20 0.31
ALDH1A1 P00352 4/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5877411 0.97 NR1H2 (0.33) HTR6MAPTUSP2MAPK1NR1H2
SCHEMBL5876198 0.90 USP2 (0.37) HTR6USP2MAPK1NR1H2NR1H3
SCHEMBL5876235 0.89 HTR6 (0.34) HTR6MAPTUSP2MAPK1NR1H2
SCHEMBL5876978 0.88 NR1H2 (0.34) MAPTNR1H2NR1H3GBA1LMNA
SCHEMBL5876674 0.88 USP2 (0.35) HTR6USP2MAPK1NR1H2NR1H3
SCHEMBL5877418 0.87 ALDH1A1 (0.36) USP2MAPK1NR1H2NR1H3NOD2
SCHEMBL5876012 0.87 NR1H2 (0.36) MAPTUSP2MAPK1NR1H2NR1H3
SCHEMBL5877895 0.85 NPC1 (0.33) HTR6MAPTUSP2MAPK1NR1H2
SCHEMBL5876201 0.85 USP2 (0.34) MAPTUSP2MAPK1NR1H2NR1H3
SCHEMBL5876077 0.85 GBA1 (0.33) HTR6USP2MAPK1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT HTR6 151/4885MAPT 1879/4885USP2 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.